Valuation: Intensity Therapeutics, Inc.

Market Cap 11.87M 10.4M 9.65M 8.87M 16.71M 1.14B 16.96M 115M 45M 560M 44.54M 43.58M 1.94B P/E 2026 *
-1.2x
P/E 2027 * -1.31x
Enterprise Value 11.87M 10.4M 9.65M 8.87M 16.71M 1.14B 16.96M 115M 45M 560M 44.54M 43.58M 1.94B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Intensity Therapeutics, Inc.

1 day-0.23%
1 week-9.30%
Current month+7.07%
1 month+11.56%
3 months-16.06%
6 months-56.57%
Current year-57.19%
1 week 4.37
Extreme 4.3678
4.87
1 month 3.8
Extreme 3.7996
5
Current year 3.51
Extreme 3.51
11.07
1 year 3.51
Extreme 3.51
43.5
3 years 3.51
Extreme 3.51
286
5 years 3.51
Extreme 3.51
286
10 years 3.51
Extreme 3.51
286
Manager TitleAgeSince
Chief Executive Officer 67 01/04/2012
Director of Finance/CFO 57 11/12/2023
Corporate Officer/Principal - 01/09/2023
Director TitleAgeSince
Director/Board Member 66 01/05/2018
Chairman 67 01/04/2012
Director/Board Member 64 14/05/2024
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Free

Controller/Auditor

11,000 0.4070%
16/07/26 Free

Director

5,500 0.2035%
16/07/26 Free

Director

5,500 0.2035%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%-9.30%-42.80%-97.22% 11.87M
+2.14%-4.80%-4.03%+12.79% 46.06B
-0.14%-0.76%+378.26%+583.71% 38.91B
+0.39%+2.79%+8.23%+61.99% 35.57B
-1.54%-4.01%+5.95%-13.03% 33.13B
-0.87%-3.19%-1.27%+29.16% 26.42B
-1.28%-6.20% - - 16.61B
-0.67%-0.21%+10.55%+115.31% 15.08B
-6.72%-5.32%+3.85%+7.52% 14.08B
+0.40%-2.79%+3.58%-31.98% 12.81B
Average -0.89%-2.96%+40.26%+74.25% 23.87B
Weighted average by Cap. -0.42%-2.60%+68.66%+122.84%

Financials

2026 *2027 *
Net sales - -
Net income -10.9M -9.55M -8.87M -8.15M -15.35M -1.05B -15.58M -106M -41.34M -515M -40.92M -40.04M -1.78B -13.3M -11.65M -10.82M -9.94M -18.73M -1.28B -19.01M -129M -50.44M -628M -49.92M -48.85M -2.17B
Net Debt - -
Logo Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Employees
6
Date Price Change Volume
22/07/26 $4.390 -0.23% 4,835
21/07/26 $4.400 -6.38% 23,519
20/07/26 $4.700 -1.05% 24,614
17/07/26 $4.750 -3.06% 19,766
16/07/26 $4.900 +1.24% 17,515
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.390USD
Average target price
24.80USD
Spread / Average Target
+464.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INTS Stock